Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

379 results about "Premalignant Neoplasm" patented technology

A neoplasm that is composed of dysplastic cells and there is no morphologic evidence of infiltration of the surrounding tissues.

Application of PARPi sensitizer in treatment of malignant tumors

ActiveCN119185316AOrganic active ingredientsMicrobiological testing/measurementNon malignantSynthetic lethality
The invention provides application of a PARPi sensitizer in treatment of malignant tumors, and particularly relates to the technical field of biological medicines. A large number of experiments prove that TRMT10A is crucial for recruitment from BRCA1 to DNA damage sites for the first time, so that HR repair is promoted. The deletion of TRMT10A inhibits HR repair, so that tumor cells are more sensitive to PARPi. The invention discloses that the expression of TRMT10A in mCRPC is up-regulated, and the TRMT10A is regulated and controlled by ubiquitin specific peptidase 10 (USP10). Spautin-1 significantly results in the deficiency of TRMT10A, and sensitizes the tumor to PARPi in both patient-derived xenograft (PDX) and cell-derived xenograft (CDX). The research reveals that the ATM-TRMT10A-BRCA1 axis plays an important role in sensibilization of the PARP inhibitor, and a new angle is provided for exploring synthesis lethality. The mechanism can be therapeutically utilized through the combination of PARPi and Spautin-1, which may benefit more extensive patients with non-BRCA malignant tumors, and has important clinical significance.
Owner:CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI

Devices, systems and methods for the treatment of abnormal tissue

Devices, systems and methods are provided to treat damaged, diseased, abnormal, obstructive, cancerous or undesired tissue (e.g. a tumor, a benign tumor, a malignant tumor, a cyst, or an area of diseased tissue, etc) by delivering specialized pulsed electric field (PEF) energy to target tissue areas. The energy is delivered in a manner so as to be non-thermal (i.e. below a threshold for causing thermal ablation). Consequently, when extracellular matrices present, the extracellular matrices are preserved, and the targeted tissue maintains its structural architecture including blood vessels and lymphatics. Thus, sensitive structures, such as biological lumens, blood vessels, nerves, etc, are preserved which are critical to maintaining the integrity and functionality of the tissue. The energy is delivered with the use of systems and devices advantageously designed for superior access to target tissue throughout the body, particularly in locations previously considered inaccessible to percutaneous approaches.
Owner:GALVANIZE THERAPEUTICS INC

Compound DOTA-HX2-DZ and application thereof

The invention provides a compound DOTA-HX2-DZ and application thereof, and belongs to the technical field of biological medicine. According to the invention, the molecular structure of DZ-HX2-DOTA is optimized, and a special connexon is designed and adopted, so that the problem of limited anti-tumor curative effect caused by poorer stability, fat solubility, tumor residence time and other properties of a radiolabeled drug in the prior art is solved. The compound provided by the invention can significantly reduce the risk of label removal of radioactive metal ions in an in-vivo environment, and ensures that the compound stably plays a role at a targeted part; the compound has excellent molecular lipid solubility, can penetrate cell membranes and vascular barriers more easily, improves the bioavailability of drugs, prolongs the in-vivo circulation time, prolongs the tumor residence time, and further improves the treatment efficiency. The DZ-HX2-DOTA disclosed by the invention has broad-spectrum tumor targeting property, and can be used for diagnosing and treating various types of malignant tumors.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV

KLRB1 binding agents and methods of use thereof

KLRB1 binding agents (in particular anti-KLRB1 antibodies and antigen binding portion thereof) and compositions thereof, as well as therapeutic methods of using the agents, e.g., for depleting cells or inhibiting cells or activating cells (in particular, Th17, Th17.1, ex-Th17, Tc17, MAIT, INKT, peTh2, ILC2, ILC3, NK cells, and / or neoplastic T or NK cells in vivo), for the treatment of autoimmune disease, allergic diseases, transplant rejection, hematologic malignancies, and cancer.
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC

Immune response to pulsed electric field therapy

Treatment of damaged, diseased, abnormal, obstructive, cancerous or undesired tissue (e.g. a tumor, a benign tumor, a malignant tumor, a cyst, or an area of diseased tissue, etc) is provided by delivering specialized pulsed electric field energy to target tissue areas in a specific dose so as to obtain a superior outcome. The specialized PEF energy and delivery has been optimized to provide advanced treatment of target tissue areas, including destruction of undesired tissue and generation of improved inflammatory and immune responses. The specialized PEF energy provides superior outcomes to radiofrequency ablation and irreversible electroporation.
Owner:GALVANIZE THERAPEUTICS INC

Radionuclide-labeled PD-L1 targeting small protein as well as preparation method and application thereof

The invention provides a radionuclide-labeled PDL1 targeting small protein as well as a preparation method and application thereof. Specifically, the invention provides a radionuclide-labeled PD-L1 targeted small protein probe and a preparation method thereof, and the radionuclide-labeled PD-L1 targeted small protein probe is used for diagnosis of malignant tumors, accurate positioning of focuses, curative effect monitoring and radioimmunotherapy. The small protein conjugate provided by the invention can be prepared by labeling in a temperature range from room temperature to 60 DEG C, and compared with other nuclides or linkers, the coupling efficiency is higher, and the finished product is more stable.
Owner:GENERAL HOSPITAL OF PLA

T-cell receptor (TCR) and use thereof

Provided are a T-cell receptor (TCR) and the use thereof, wherein the TCR contains an α chain containing a variable region and / or a β chain containing a variable region. The TCR is capable of specifically recognizing an A1101-restricted KRASG12V mutation and an A1101-restricted KRASG12D mutation. A T cell transducing the TCR (TCR-T) can bind to an antigen short peptide-HLA-A1101 complex, and can be used for treating malignant tumors carrying the KRASG12V mutation and KRASG12D mutation.
Owner:GUANGZHOU MEDICAL UNIV

KLRB1 binding agents and methods of use thereof

KLRB1 binding agents (in particular anti-KLRB1-antibodies and antigen binding portion thereof) with increased humanness and compositions thereof, as well as therapeutic methods of using the agents, e.g., for depleting cells or inhibiting cells or activating cells, (in particular, Th17, Th17.1, ex-Th17, Tc17, MAIT, iNKT, peTh2, ILC2, ILC3, NK cells, and / or neoplastic T or NK cells in vivo), for the treatment of autoimmune disease, allergic diseases, transplant rejection, hematologic malignancies, and cancer.
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC

Controlled lesion and immune response to pulsed electric field therapy

Treatment of damaged, diseased, abnormal, obstructive, cancerous or undesired tissue (e.g. a tumor, a benign tumor, a malignant tumor, a cyst, or an area of diseased tissue, etc) is provided by delivering specialized pulsed electric field (PEF) energy to target tissue areas in a specific dose so as to obtain a superior outcome. The PEF energy and delivery has been optimized to provide advanced treatment of target tissue areas, including destruction of undesired tissue and generation of improved inflammatory and immune responses. These various types of treatment are controlled by a variety of factors including the electrode geometry, the dose of PEF energy delivered, the time the energy is delivered over, and the waveform of the PEF energy itself. The PEF energy is delivered in the form a dose which is considered to be one application of the specialized energy. Each dose creates a lesion in the target tissue area.
Owner:GALVANIZE THERAPEUTICS INC

Application of small molecule compound LZ-A4 in preparation of preparation or medicine for treating malignant tumors

The invention discloses an application of a small molecular compound LZ-A4 in preparation of a preparation or a medicine for treating malignant tumors. The chemical formula of the small molecule compound LZ-A4 is C19H11Cl2N3O3S, and the small molecule compound LZ-A4 can promote degradation of LGMN in malignant tumor cells, inhibit proliferation of tumor cells and inhibit polarization of macrophages to M2 type. The research on a colorectal cancer mouse transplantation tumor model proves that the development of the colorectal cancer can be effectively inhibited by single treatment of the LZ-A4, and the volume of the tumor can be further reduced after the LZ-A4 is combined with a clinical first-line chemotherapeutic drug Oxaliplatin for the colorectal cancer. Meanwhile, the LZ-A4 can inhibit M2 type polarization of macrophages in a tumor microenvironment in vivo, promote infiltration of cytotoxic T cells, remodel the tumor microenvironment and activate anti-tumor immunity. In addition, the A4 has good toxic and side effects, and does not cause further reduction of the body weight of the mouse after being combined with chemotherapeutic drugs.
Owner:LIANGZHU LAB

Digestive tract malignant tumor metastasis risk assessment method and system based on artificial intelligence

The invention discloses a digestive tract malignant tumor metastasis risk assessment method and system based on artificial intelligence, and relates to the field of digestive tract malignant tumor metastasis risk assessment. The method comprises the following steps: firstly, acquiring PET-CT three-dimensional image data of a colorectal cancer patient, and constructing and extracting a three-dimensional voxel matrix of a liver region according to the PET-CT three-dimensional image data; inputting the voxel matrix of the liver region into a pre-trained convolutional neural network model, and outputting a probability distribution matrix of each voxel; setting a basic confidence threshold of the malignant tumor metastasis, and extracting candidate focuses according to the probability distribution matrix and the confidence threshold of the malignant tumor metastasis; obtaining the maximum diameter of the candidate focus, dynamically and adaptively adjusting the confidence coefficient threshold value of the malignant tumor metastasis focus according to the maximum diameter, and generating a binary mask matrix; calculating a comprehensive risk score of colorectal cancer liver metastasis according to the binary mask matrix and grading; according to the invention, the false positive inhibition capability can be enhanced and the risk assessment accuracy can be improved.
Owner:FUJIAN PROVINCIAL HOSPITAL

Heterocyclic compound and application thereof

The invention relates to a heterocyclic compound and application thereof.The structure of the heterocyclic compound is shown as a formula (I) or a formula (II), experiments prove that the heterocyclic compound can efficiently degrade CK1alpha through a molecular glue mechanism, so that a p53 pathway, a Wnt / beta-catenin pathway, an ATM pathway and the like are affected, and the heterocyclic compound can be used for preventing or treating diseases caused by abnormally high expression of CK1alpha, and can be used for treating diseases such as diseases caused by abnormally high expression of CK1alpha. The compound can be used for preparing medicines for treating malignant tumors and solid tumors of a blood system, especially medicines for treating acute myeloid leukemia.
Owner:PUDU ZHONGHE (WUHAN) LIFE TECH CO LTD

Combination therapy of benfo-oxythiamine (B-OT) and / or oxythiamine (OT) together with radionuclide therapy in patients with tumors, especially malignancies (cancerous tumors)

Benfo-oxythiamine (B-OT) and / or oxythiamine (OT) are administered as active substances concurrently with ongoing radionuclide therapy (RNT), particularly radioimmunotherapy (RIT) and / or radiopeptide or radioligand or radiopeptide ligand therapy (RLT), in the treatment of patients with tumors, especially malignant tumors. B-OT and / or OT administration is cyclical, meaning that phases of B-OT and / or OT administration ("B-OT / OT administration cycles") alternate with treatment breaks (administration breaks). In each B-OT / OT administration cycle, B-OT and / or OT is administered on one or more consecutive days at a predetermined dose (mg per kg of the patient's body weight). This is followed by a treatment break in which neither B-OT nor OT is administered, and then the next B-OT / OT administration cycle.
Owner:TAVARGENIX GMBH

Method of treating malignant tumor by azabicyclic compound

Provided is a method of treating malignant tumor by an azabicyclic compound, particularly, with eye disorder reduced. The present invention provides a method for treating malignant tumor, comprising administering an effective amount of 3-ethyl-4-[3-(1-methylethyl)-4-[4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl]-1H-pyrazolo[3,4-b]pyridin-1-yl]benzamide (compound 1) or a salt thereof to a patient in need thereof according to a dosing regimen, wherein the dosing regimen comprises administering the compound 1 or the salt thereof at a dose from 40 mg / body / day to 240 mg / body / day in terms of the amount of the compound 1 for consecutive days, and then providing a withdrawal period of at least 2 days.
Owner:TAIHO PHARMA CO LTD

DARC expression as prognosticator of immunotherapy outcomes

Methods for prognosticating if an individual afflicted with a malignant tumor is likely to respond favorably to immunotherapy comprising testing for the presence or absence of DARC expression in the tumor, and if no DARC expression is detected, identifying the individual as not being suitable for immunotherapy, and optionally administering an anti-cancer therapy other than immunotherapy to the individual, or if DARC expression is detected, then identifying the individual as being suitable for immunotherapy, and optionally administering immunotherapy or any other anti-cancer therapy to the individual.
Owner:CORNELL UNIVERSITY

Chitosan-derived compositions

Therapeutic compositions comprising chitosan-derived compositions are useful agents when administered in connection with methods for treating neoplasms, such as for instance, malignant lung, thyroid and kidney neoplasms, and other types of malignant neoplasms, and other medical disorders.
Owner:IMMUNOPHOTONICS INC

Biomarker tRF-Arg-CCG-019 and application thereof in preparation of lung cancer diagnosis product

The invention discloses a biomarker tRF-Arg-CCG-019 and application of the biomarker tRF-Arg-CCG-019 in preparation of a lung cancer diagnosis product, and belongs to the technical field of molecular biology. The nucleotide sequence of the biomarker tRF-Arg-CCG-019 is AGGTAATCCGGTGCGCCGG (SEQ ID NO.1), the expression level of the biomarker tRF-Arg-CCG-019 in lung cancer tissues (malignant tumor tissues) is obviously higher than that of para-carcinoma tissues, the biomarker tRF-Arg-CCG-019 can be used as a biomarker for early diagnosis of lung cancer, the sensitivity is 88%, the specificity is 92.9%, and the early diagnosis of lung cancer can be simply and quickly carried out by utilizing the molecule.
Owner:JIANGSU CANCER HOSPITAL

Application of micro peptide MIAC

The invention discloses application of a micropeptide MIAC, and belongs to the technical field of biological medicines. In particular to application of the micro peptide MIAC in preparation of a reagent or a medicine for detecting, preventing or treating tumors. The tumors comprise one or more of solid tumors such as pancreatic cancer, liver cancer, colorectal cancer, ovarian cancer, cervical cancer, bladder cancer, melanoma, glioblastoma, neuroblastoma, glioma, osteosarcoma, lymphoma, hematoma, myeloma, cholangiocarcinoma, prostatic cancer and the like and hematoma. The micropeptide MIAC has the effects of inhibiting growth, proliferation and / or migration of various tumor cells, is wide in treatment spectrum, and is suitable for diagnosis, prevention or treatment of various tumors, especially malignant tumors.
Owner:NANJING ANJI BIOLOGICAL TECH CO LTD

Bionic nanoparticle, composition, preparation method and application thereof

The invention discloses bionic nanoparticles, a composition, a preparation method and application thereof, and relates to the technical field of red blood cell-cancer cell hybrid membrane bionics. The bionic nanoparticles comprise lipidosome and a hybrid membrane coated on the surface of the lipidosome, drugs are coated in the lipidosome, and the drugs are astragaloside and curcumin; the molar ratio of the medicine to the liposome is 1: 15; the hybrid membrane is a hybrid membrane of an erythrocyte membrane and a cancer cell membrane. The erythrocyte-cancer cell hybrid membrane wraps the outer layer of the liposome phospholipid bilayer to construct the nano targeting drug delivery system, the modification of the hybrid cell membrane integrates the advantages of long circulation, immune escape, homologous targeting and the like, and a new treatment mode is developed for immunotherapy of malignant tumors with low response rate. The hybrid membrane can improve the targeting property of the drug, reduce side effects on patients and improve the tolerance of the patients. The medicine can be coated in an aqueous solution layer of the liposome, so that the water solubility of the medicine is improved, and meanwhile, the anti-tumor effect of the medicine can be enhanced.
Owner:SICHUAN ACADEMY OF MEDICAL SCI SICHUAN PROVINCIAL PEOPLES HOSPITAL

Scoring methods for anti-PD therapy eligibility and compositions for performing same

Aspects of the present disclosure provide methods for determining the eligibility of a subject having a malignancy for treatment with an anti-PD therapeutic agent based on a Combined Positive Score (CPS) for a tumor tissue sample from the subject. Compositions and kits or performing the disclosed methods are also provided.
Owner:MERCK SHARP & DOHME LLC +1

A fusion film-wrapped composite nanodelivery system, and a preparation method and application thereof

PendingCN122297701AFusobacteriaDrug release
This invention discloses a composite nanodelivery system encapsulated in a fusion membrane, its preparation method, and its applications. The nanodelivery system comprises a Ti3C2 / TiO2 / CuInS2 composite material, oxaliplatin loaded thereon, and a fusion membrane encapsulating the outer layer; the fusion membrane is formed by the fusion of Fusobacterium nucleatum extravesicles and M1 macrophage membranes. This invention also discloses a method for preparing the nanodelivery system, including the steps of preparing the Ti3C2 / TiO2 / CuInS2 composite material, preparing the fusion membrane, loading oxaliplatin, and encapsulating it in the fusion membrane. The nanodelivery system prepared by this invention exhibits pH-responsive drug release characteristics, generating H2S in the tumor microenvironment and H2 under light irradiation, while also possessing photocatalytic activity. This invention combines chemotherapy, photoelectrocatalytic therapy, and the regulation of multiple active substances, and can be used to prepare drugs for treating malignant tumors of the digestive system.
Owner:NINGBO MEDICAL CENT LIHUILI HOSPITACL

New Application of Jiawei Xihuang Pill in the Prevention and Treatment of Malignant Tumors

This invention provides the application of Jiawei Xihuang Pill (MXHP) in the preparation of drugs for the prevention and / or treatment of malignant tumors. This invention also provides the application of Jiawei Xihuang Pill in combination with chemotherapy drugs for the prevention and / or treatment of malignant tumors, particularly glioblastoma multiforme (GBM), wherein the active ingredients of Jiawei Xihuang Pill are prepared from bezoar, musk, vinegar-processed frankincense, vinegar-processed myrrh, and Panax notoginseng root extract in a weight ratio of 14-16:14-16:545-555:545-555:245-255. MXHP can synergistically inhibit the growth of glioblastoma in situ and induce tumor cell apoptosis, indicating that MXHP may be a potential therapeutic drug. Furthermore, compared to XHP, MXHP significantly prolongs the median survival of GBM, exhibiting an enhanced anti-GBM effect.
Owner:SOUTHERN MEDICAL UNIVERSITY

Bispecific GPC3xCD28 and GPC3xCD3 antibodies and combinations thereof for targeted killing of GPC3-positive malignant cells

The present invention relates to a GPC3xCD3 bispecific antibody, a GPC3xCD28 bispecific antibody, and a combination of two agonistic fully human κλ antibodies, one targeting GPC3xCD3 and the other targeting GPC3xCD28, both of which do not compete for binding to GPC3. The present invention also relates to the use of the bispecific antibodies for the treatment of GPC3-positive malignancies.
Owner:ラムキャップ バイオ ガンマ エージー

Medical compounds

The present invention provides a medicinal compound comprising a synthetic flavonoid derivative according to formula (I), which has a group at the C-3 position: wherein at least two of R2-R6 are H, and the rest are independently selected from: H, OH, R1, OR1, NO2, NH2, NHR1, F, Cl, Br, I; wherein R1 is a free radical. The present invention also provides dimerization, trimerization and tetramerization compounds, wherein two or more quercetin units are connected to a central linker (skeleton) via position 3 and a spacer. The medicinal compound can be used to treat malignant tumors, in particular malignant epithelial tumors, such as colon cancer, melanoma and / or squamous cell carcinoma of the skin, lung cancer, breast cancer, basal cell carcinoma (basal cell tumor). #imgabs0#
Owner:VERA SALUS RICERCA SRL

Application of TRK inhibitor LYS-8 in preparation of medicine for treating malignant tumors

The invention belongs to the field of molecular biology, particularly relates to the field of tumor treatment, and particularly relates to application of a TRK inhibitor LYS-8 in preparation of a medicine for treating malignant tumors, particularly pancreatic cancer. LYS-8 is a small molecule TRK inhibitor with a novel structure, and research finds that LYS-8 can significantly inhibit TRK kinase activity and down-regulate downstream PI3K-AKT and other signal channels. Experimental results show that the inhibition effect of LYS-8 in pancreatic cancer cells is obviously superior to that of colorectal cancer cells, and the IC50 value of LYS-8 is lower; in an animal model, the tumor inhibition rate of LYS-8 on pancreatic cancer reaches about 70%, and the inhibition rate on colorectal cancer is about 56%, which is obviously superior to that of a colorectal cancer model. The invention reveals that LYS-8 has an unexpected curative effect advantage on pancreatic cancer, and a new drug choice is provided for targeted therapy of pancreatic cancer.
Owner:CHINA PHARM UNIV

CD97 and gsdme interaction inhibitor having Anti-tumor activity and application thereof

The disclosure belongs to the technical field of medicine. Provided are a CD97 and GSDME interaction inhibitor having anti-tumor activity and an application thereof. A compound screened in the disclosure enhances the susceptibility of NK cells to kill tumor cells by inhibiting the interaction between GSDME and CD97 in tumor cells, so as to induce an immune anti-tumor effect. Moreover, the compound enhances the susceptibility of tumor cells to pyroptosis by blocking the protective effect of CD97 on cleavage of GSDME proteins. Therefore, the compound can be used for treating GSDME and CD97 double-positive malignant tumors, and combined chemotherapy, immunotherapy, etc., to enhance the susceptibility of malignant tumors to chemotherapy and immunotherapy, prolonging the overall survival period of patients with malignant tumors. Specifically provided is a compound having a structure set forth in formula (I), a pharmaceutically acceptable salt, a solvent compound or a deuterated compound thereof.
Owner:JILIN UNIVERSITY

Method for treating gynecological malignant tumors by anti-HER2 antibody drug conjugate and application of anti-HER2 antibody drug conjugate

The present disclosure relates to methods and uses of anti-HER2 antibody drug conjugates for treatment of gynecological malignant tumors. Specifically, the invention relates to application of the anti-HER2 antibody drug conjugate in preparation of drugs for treating gynecological malignant tumors expressed by HER2, and the structure of the antibody drug conjugate is shown as a formula (I). # imgabs0 #
Owner:JIANGSU HENGRUI MEDICINE CO LTD

Insulin receptor modulation for tumor associated hyperinsulinism

PCT designated stageWO2025171378A1Metabolism disorderAntibody ingredientsAnti-insulin receptor antibodyAntiendomysial antibodies
The present disclosure describes the use of an anti-insulin receptor antibody to treat neoplasms and / or tumor-associated hyperinsulinism and resulting hypoglycemia caused by benign or malignant neoplastic production of insulin and / or other effector substances (e.g., IGF-2 or its variants) that interact with the INSR and thus result in insulin-like action.
Owner:REZOLUTE INC